NEW YORK and HOUSTON, Oct. 15, 2025 — Grafine Partners (“Grafine”), a specialized investment firm that seeds and co-invests alongside emerging private equity managers with deep sector expertise and proven track records, today announced a strategic partnership with Amberjack Capital Partners (“Amberjack”). Amberjack, headquartered in Houston and run by Managing Partner Jason Turowsky, is a private equity firm that makes control investments in lower middle market businesses within the Infrastructure & Industrial Services and Waste & Environmental Services sectors. Financial terms of the partnership were not disclosed.

Elizabeth Weymouth, Founder and Managing Partner at Grafine, commented, “Jason and the Amberjack team have built a distinctive private investment platform. They exemplify the experienced and entrepreneurial investors we seek to partner with – those pursuing differentiated strategies that seek to generate strong, risk-adjusted returns. We are thrilled to support Amberjack in their next phase of growth.”

“This strategic partnership with Grafine will enhance our ability to continue growing as a firm and investing in the lower middle market critical infrastructure services sector,” said Mr. Turowsky. “This sector includes a diverse range of businesses with compelling opportunities for growth, driven by secular tailwinds such as the need to modernize aging assets, reshore U.S. production, and meet increasing power demand.”

Mr. Turowsky added, “Grafine is a true strategic partner to us — their experience, insight, and global network will add value beyond capital, accelerating Amberjack’s growth.”

Amberjack partners with entrepreneurs, managers, and business owners – typically as the first institutional capital provider – bringing company-building expertise to drive growth and long-term value creation. The firm focuses on building institutional-quality companies by providing strategic capital, enhancing operational efficiency, implementing governance best practices, and strengthening leadership teams.

Amberjack represents the final investment in Grafine Capital I, Grafine’s inaugural seeding strategy, which closed in early 2024 with approximately $600 million in total capital commitments. In addition to its seeding strategy, Grafine also has a co-investment and direct investment platform.  

Kirkland & Ellis served as legal advisor to Grafine. Davis Polk & Wardwell LLP served as legal advisor to Amberjack.

About Grafine Partners

Grafine Partners, founded by Elizabeth Weymouth, is an alternative investment management firm created to meet the needs of sophisticated institutional investors seeking innovative approaches to invest private capital with a focus on alignment of incentives. Grafine’s differentiated focus allows it to source unique investment opportunities and execute on direct deals across a range of industry sectors, geographies, and capital structures that align with the evolving needs of its institutional investor network. Through a pioneering investment approach, Grafine acts as a principal investor to seed and build private investment firms alongside the next generation of talented private market investors and operating partners. For more information, please visit www.grafine.com.

About Amberjack Capital Partners

Amberjack Capital, headquartered in Houston, TX, is a private equity firm that invests in and partners with entrepreneurs and business owners to build market leaders serving the industrial, infrastructure and environmental end markets. Often the first institutional investor in founder-led companies, Amberjack has a particular focus on supporting high performing companies undertaking strategic or transformative initiatives.

Media Contacts

For Grafine Partners
Zach Kouwe/Jansel Murad
Dukas Linden Public Relations
[email protected]

For Amberjack Capital Partners
Alex Jeffrey
Gasthalter & Co.
[email protected]

SOURCE Grafine Partners

ST. MORITZ, Switzerland, Oct. 15, 2025 — The CfC St. Moritz, a highly curated digital assets and blockchain conference for investors and decision-makers, which is set to return from January 14-16, 2026, has announced additions to its speaker lineup.

The updated speaker list includes:

• Brad Garlinghouse, CEO of Ripple
• Lily Liu, President at Solana Foundation
• Fred Thiel, Chairman & CEO at MARA Holdings
• Sheila Warren, Chief Executive Officer at Project Liberty Institute; Chief Strategy & Operations Officer at Project Liberty
• Carlos Domingo, Founder & CEO at Securitize
• Talia Klein, Managing Director & Head of Wealth Management Services at the DTCC
• Anton Katz, Co-Founder & CEO at Talos
• Ambre Soubiran, CEO at Kaiko
• Michael Higgins, International CEO & Global Head of Corporate Development at Hidden Road
• Teresa Goody Guillén, Partner at Baker & Hostetler LLP
• Javier Rodriguez, CCO at XBTO
• Robinson Burkey, Co-Founder at Wormhole Foundation
• John Nahas, Chief Business Officer at Ava Labs
• Amar Kuchinad, CEO at Copper
• Evgeny Gaevoy, Founder & CEO at Wintermute        

Nicolo Stöhr, CEO of the CfC St. Moritz, said: “I’m delighted to announce our second group of speakers, each bringing unique expertise across crypto, regulation, traditional finance, and innovation. The breadth of these speakers underscores our goal to foster a truly integrated dialogue among the most influential voices in the ecosystem. As we approach 2026, I am confident that CfC St. Moritz will once again be the place where ideas converge, giving key leaders the platform they need to define the course for the year ahead in what is shaping up to be a momentous time.”

Held at Suvretta House, nestled in the Swiss Alps, the CfC St. Moritz brings together global industry experts, business leaders, and regulators from across crypto, finance, and technology to discuss the most prevalent issues and trends for the year ahead. There are only 250 places available for participants, and seats are allocated based on strict criteria, ensuring a productive environment for the most important figureheads in the tech, finance, crypto, and policy industries. Submissions for applications will open on October 15, 2025, and interested parties can visit the website for more information.

Sheila Warren, CEO of the Project Liberty Institute and Ambassador to the CfC St Moritz, said: “The 2026 edition of CfC St. Moritz comes at a defining moment for the digital assets industry. As global interest accelerates and regulatory frameworks take shape, this gathering offers a rare opportunity for leaders across finance, policy, and technology to come together, share insights, and help shape the next phase of the industry. I’m looking forward to another year of meaningful dialogue, new connections, and real momentum.”

Before the main conference begins, the CfC St. Moritz will once again host its signature Pre-Opening on January 12-13, 2026, offering attendees a relaxed, informal environment to connect and network ahead of the core program. Participants will have the opportunity to choose from a curated selection of alpine activities, from skiing and snowshoeing to spa experiences and private lunches, set against the breathtaking backdrop of the Engadin Valley. This unique tradition has become a hallmark of the CfC St. Moritz experience, setting the tone for meaningful conversation, connection, and collaboration.

About the CfC St. Moritz

The CfC St. Moritz is an intimate circle of hand-picked opinion leaders and investors in the private and unique setting of the Swiss Alps. The yearly application-only conference fosters a culture of genuine connection and deliberately admits a maximum of only 250 international UHNWI, family offices, funds, and institutional investors, uniting the traditional finance sector and the crypto industry. The CfC St. Moritz was founded in 2017 and has since conducted seven in-person conferences in St. Moritz, one in Half Moon Bay, California, two virtual conferences during the pandemic, and several smaller events.

www.cfc-stmoritz.com  | LinkedIn | Twitter | Instagram

SOURCE CfC St. Moritz

SAN FRANCISCO, Oct. 14, 2025 — We are delighted to announce Ren Crypto Fish’s new role at Electric Capital as a General Partner. Ren exemplifies our engineering-lead investment approach. He combines technical depth with investment insights – using his understanding of protocol design, security, and engineering talent to spot and back high-conviction opportunities at the frontier of technology.

Electric Capital’s Approach: We hire engineers, not investors
We have always believed the next generation of iconic venture firms will be led by software engineers because all markets will be crypto-enabled. As value becomes digital, new technologies to transfer and aggregate value will naturally emerge. Decentralized exchanges, on-chain treasuries, and algorithmic markets are demonstrating how liquidity, risk, and value can move transparently across borders and time zones.

Engineering capability and technical understanding are essential to helping founders succeed on these open platforms. VCs will need expertise in areas such as execution systems, governance mechanisms, code security, and liquidity provisioning.

In the on-chain world, capital deployment is not only software-enabled, it is only possible with software. To invest in a financial system that runs on code, we must build software ourselves to interface with this new world. Electric Capital’s engineering team helps deploy capital, participate in protocols, perform technical diligence, and harness custom data sources to inform investment decisions.

Ren’s career began as a Quantitative Researcher at Citadel where he built infrastructure from the ground up for oil and natural gas markets, incorporating information at the deepest level of granularity to drive market decisions. This experience gave him deep intuition for liquidity, volatility, and system design. He brings that expertise to crypto, where on-chain markets are evolving faster than any prior financial system.

From a cold DM to shaping the future of crypto markets
Ren originally found Electric Capital through a cold DM on Twitter in April 2021 asking about developer data. What began as a thoughtful question turned into years of collaboration. Ren’s intellectual curiosity and commitment to understanding how crypto, fintech, and compute markets evolve have made him a core part of how we invest.

Ren is deeply technical and joined us as a software engineer. He co-created Codeslaw, the open search smart contract tool used by hundreds of security researchers in crypto. He co-authored a paper analyzing the game theory of Bitcoin consensus mechanism, its dynamics during consensus changes, and continues to contribute to “Bitcoin Consensus Analysis Project.” He developed Smart Contract Genealogy Analysis with methods to detect novel logic in deployed smart contracts by fingerprinting control flow graphs used in Electric Capital’s Developer Report to study contract evolution across EVM chains. He has built internal systems for monitoring liquidity and developer activity across ecosystems. Ren is also clearly crypto-native. He is perhaps the only pseudonymous general partner at an institutional venture capital firm. All of this has made him tremendously impactful as a member of our investment team and tremendously valuable as a collaborator with founders in the ecosystem.

Ren has been instrumental in our investments in Solana, Monad, Unto, Ellipsis, Kuru, and Asula, among others. His insights on market microstructure, execution pathways, and the interplay between code and capital have shaped how we think about this new generation of networks.

Ren consistently pushes our thinking on how technology, liquidity, and governance intersect. His analyses of validator incentives, market depth, and cross-domain composability inform both our investment decisions and how we engage with the broader crypto community. We are grateful to have him with us. We know the founders he works with feel the same way.

Welcome Ren, our newest General Partner at Electric Capital.

About Electric Capital

Electric Capital is a top early-stage venture firm that invests in the next generation of iconic frontier technology founders. With over $3B in assets under management, we leverage deep expertise in cryptography, distributed systems, and machine learning to identify and support founders shaping the future.

We’re often the first check into transformative companies. We invest at the idea stage and partner with founders through launch and scale. Our portfolio includes category-defining projects like Aven, Bitnomial, Bitwise, Ellipsis, Kraken, Magic Eden, Monad, NEAR, Solana, and Re. Prior to Electric, our partners were early investors in companies like Airtable, Anchorage, Boom Supersonic, Color Genomics, Cruise, Figma, Material Security, Newfront Insurance, Notion, and Pulley.

Electric team members have collectively started eight companies (six acquired), shipped products used by billions of people, run billion-dollar business units, invested in 50+ startups that have a cumulative market cap of $50B+, and traded billions in esoteric derivatives. We partner actively with founders to solve complex technical and strategic challenges. Our offices are in San Francisco, New York, Toronto, and Tokyo. Find us at www.electriccapital.com.

Contact:
[email protected]

SOURCE Electric Capital

Spun out from Arup, Class 3 leverages deep engineering expertise with advanced modeling to deliver unprecedented clarity for decision-makers managing climate risk

SAN FRANCISCO, Oct. 14, 2025 — Class 3 Technologies (Class 3), a startup pioneering the next-generation of climate risk and resilience modeling for the built environment, today announces the close of its $3.5M seed round led by Powerhouse Ventures alongside Sustainable Future Ventures and Tailwind Futures. Spun out of the global engineering and built environment consultancy Arup, Class 3 exits stealth with Iris — a first-of-its-kind platform delivering actionable, building-level insights to help organizations quantify and manage the growing threat of climate-driven disasters.

Beyond reporting, confidence to take action

A growing number of organizations that operate, own, or invest in properties want to limit their potential impact to catastrophic events and protect their people, property, and businesses. They recognize that legacy tools built for financial reporting do not provide enough details to make critical real estate or operational decisions. While high-quality engineering assessments exist, they are cost-prohibitive at scale, limiting accessibility and impeding needed progress on global risk reduction. A revolutionary approach that delivers unprecedented accuracy and scalability at the building level was necessary to equip decision-makers with the intelligence to take action with confidence.

Built on two decades of frontline engineering and building design experience, Iris represents a step-change in how climate risk can be measured and managed. While traditional platforms rely on high-level projections or insurance-based loss averages, Iris translates state-of-the-art engineering methodologies into detailed vulnerability assessments and resilience strategies tailored to the unique characteristics of each building.

Class 3’s founding team brings unparalleled expertise in risk modeling, climate resilience strategy, and building engineering design and performance. CEO Ibbi Almufti, a licensed professional and structural engineer, previously led the Risk and Resilience practice at Arup, where he helped shape national and international approaches to quantify and reduce climate and seismic risk. The team is rounded out with experience in venture building and Enterprise B2B SaaS.

“We’re here to catalyze resilience action at scale,” said Ibbi Almufti, Founder and CEO of Class 3. “To measure resilience accurately we had to develop new damage and loss models built on first principles of engineering, down to the level of individual building components. With Iris, organizations can finally quantify building vulnerability and risk properly and simulate the benefits of resilience interventions to act decisively.” 

Powerhouse Ventures, an early backer of transformative climate software, led the round. “Iris is an innovative new software platform that will change the way organizations manage and protect their building and infrastructure portfolios,” said Marie Thompson, Partner at Powerhouse Ventures. “We believe Class 3’s team and technology uniquely position them to lead the next generation of resilience planning.”

Engineering at the Core, Resilience at Scale

Class 3 was born out of the world-class innovation environment at Arup, where risk and resilience experts collaborated with engineers to design buildings that can withstand earthquakes, extreme weather, and other physical hazards. Iris embodies Arup’s engineering DNA, turning deep technical expertise into a digital platform that simulates physical impacts, quantifies structural vulnerability, and tests resilience measures with precision and clarity. Recognizing Iris’s potential to drive climate resilience globally, Arup Ventures spun out Class 3 as an independent company to scale its reach. Arup Ventures supports the incubation, acceleration, scaling and commercialization of early-stage companies seeking to redefine and transform the built environment for the better.

“Class 3 translates engineering excellence into accessible software for climate resilience,” said Ilana Judah, Americas Climate and Sustainability Leader at Arup. “This launch is an exciting milestone for Arup Ventures and we will continue building on this legacy, leveraging Iris to continue to deliver the best-in-class risk and resilience consultancy work that remains core to who we are.”

Already in use by leading tech companies, investors, developers, real estate owners, insurance brokers, and consultants, Iris has been quietly deployed during the company’s stealth phase to support risk analysis and resilience strategies for a wide range of building portfolios and asset types. Today, decision-makers trust Iris for more accurate risk assessment, site selection, due diligence of acquisitions, investment in upgrades for existing portfolios, and new design and construction choices.

To learn more, visit www.class3technologies.com or follow Class 3 Technologies on LinkedIn.

Media Contact
Rebecca Birmingham
Class 3 Technologies
[email protected]

Investor Relations
Ibbi Almufti
Class 3 Technologies
[email protected]

SOURCE Class 3 Technologies

Leading AI document intelligence platform secures new funding led by Andreessen Horowitz, bringing total funding to over $100M in less than one year

SAN FRANCISCO, Oct. 14, 2025 — Reducto, the leading AI document intelligence platform, announced a new $75M Series B funding round. The round was led by Andreessen Horowitz, with participation from existing investors Benchmark, First Round Capital, BoxGroup, and YCombinator. This follows the company’s April 2025 Series A round of $24.5M and brings Reducto’s total funding to date to $108M.

Since its founding two years ago, Reducto has pioneered a new standard for document understanding by combining traditional optical character recognition (OCR) with modern Vision-Language Models (VLMs), enabling systems to read documents as a human would. Building on that foundation, the company has continued to push the frontier of how companies interact with unstructured data with releases for advanced parsing, splitting, structured document extraction, and the industry’s first AI document editing API.

“Documents contain some of the most valuable data in most industries—from healthcare to finance to logistics. Yet until now, they’ve been a bottleneck for making AI useful for real enterprise use cases,” said Adit Abraham, co-founder and CEO of Reducto. “Our vision is to build the trusted layer that connects messy, real-world data with language models—so that AI can reason over the world as it really is, not just the text that’s clean and easy.”

Since announcing their Series A 5 months ago, Reducto’s monthly processing volume has grown by more than 6x, processing close to a billion pages of data for many of the world’s leading technical teams. Customers range from fast growing AI-native startups, including Harvey, Rogo, and Scale AI, to global financial institutions and Fortune 10 enterprises. These companies rely on Reducto to handle their most complex and mission-critical document workflow, such as, converting pdfs with redlines to text in legal workflows, extracting complex charts for financial due diligence, or high-stakes figure extraction for healthcare decisions.

“Reducto has become a magic ingredient that modern AI companies build with when it comes to large scale document workloads,” said Jennifer Li, General Partner at Andreessen Horowitz. “The team not only anticipated the rise of vision language models, they’ve continuously pushed the field forward with first-party research, elegant product experience and robust infrastructure that enterprise customers love.”

Reducto’s platform already powers the end-to-end lifecycle of unstructured data, and creates LLM-ready inputs for any use case. These capabilities are delivered through both a developer-friendly API and Reducto Studio, an interactive workspace for building, evaluating, and deploying pipelines.

Reducto is now making reliable document ingestion available to everyone building with AI. The company announced that it’s introducing a new flexible pricing structure for startups and innovators who want access to the same best-in-class infrastructure used by leading enterprises. These options lower the barrier for early-stage teams and researchers, helping them start fast today, and grow with Reducto as their dedicated ingestion team for the long run.

The $75M Series B funding will accelerate development across model research and product capabilities,  and scale the company’s adoption across both enterprise and the next generation of AI teams. “Our current customers love us for our best-in-class accuracy, and we intend to continue pushing the frontier of document intelligence for them.” said Raunak Chowdhuri, co-founder and CTO of Reducto.

“Reducto is at the inflection point every ambitious builder dreams of—where the technology is proven, the market demand is exploding, and the opportunity to make an impact is massive,” said Chetan Puttagunta, General Partner at Benchmark. “If you’ve ever wanted to join a company right as it defines a new category, this is that moment. Reducto is becoming the indispensable infrastructure layer for AI, and the people who join now will help shape how the world’s most important industries adopt this technology.”

To learn more, visithttps://reducto.ai or explore open roles at https://reducto.ai/careers.

About Reducto
Reducto  is the most accurate solution for turning complex documents into AI-ready inputs. The team from MIT built state of the art vision models that read documents like humans do, solving a critical bottleneck for AI teams working with unstructured data. Reducto enables reliable AI processing of sensitive documents like medical records and financial statements with the accuracy and reliability necessary in production environments.

Having processed over a billion pages for leading enterprises, and backed by $108M in funding, Reducto has quickly become the leading platform for AI document intelligence.

SOURCE Reducto

NEW YORK, Oct. 14, 2025 — Marble, the youth mental health company building the infrastructure layer for a new teen mental health system, today announced it has raised $15.5 million in Series A funding, led by Costanoa with participation from Town Hall Ventures and Khosla Ventures. Marble will use the funding to expand access to critical mental health care in schools across the U.S. and grow its team to accelerate innovation and impact at scale.

The youth mental health crisis has reached record levels: 1 in 10 teens attempted suicide in the past year, according to CDC data. Rates of anxiety, depression, and social withdrawal are surging, yet families face severe barriers to care. Nearly half of American youth are Medicaid members, and for many, waitlists at community clinics stretch months or even years. School counselors are often the first line of defense, but with average caseloads of 385 students, they simply can’t meet the need.

One Marble parent described her experience: “I tried literally everything I could to help my son, but I couldn’t make it happen. I searched far and wide for a therapist who accepted his Medicaid plan, but found none. The school couldn’t help me either, and my son just got worse and worse. He eventually stopped speaking to me entirely, and I grew more and more concerned about his well-being.”

Founded by Jake Sussman and Dan Ross, former co-founders of Headway, the largest adult mental health provider in the country, Marble partners directly with schools to identify students in need and connect them quickly to licensed therapists. Since launching in New York last year, Marble has facilitated more than 15,000 therapy sessions for kids and families who otherwise wouldn’t have access to care. By embedding within schools and partnering with both Medicaid and commercial payers, Marble brings evidence-based therapy to students who might otherwise struggle to access care—especially those covered by public insurance.

“In my time teaching at a low-income charter school in Brooklyn, I saw students in crisis left waiting for help, while school counselors scrambled to find support that just wasn’t there,” said Jake Sussman, Marble CEO. “We built Marble to close that gap—because kids shouldn’t have to wait for help, and schools shouldn’t have to go it alone.”

Unlike traditional solutions, Marble embeds collaboration into its platform, enabling school counselors, parents, and therapists to share insights in real time. The company also reduces the administrative burden of Medicaid through tools like its AI scribe and proprietary therapist EHR, making it easier for clinicians to participate in Medicaid networks and dramatically expanding access. Marble’s group therapy programs further increase clinician capacity, enabling therapists to support more students at once while maintaining quality of care.

“Most schools want to support their students’ mental health, but they’re stretched thin and often can’t afford to bring in help,” said Amy Cheetham, Partner at Costanoa Ventures. “What stood out about Marble is that they’ve built a model where schools don’t have to pay a dime—and still get high-quality, timely care for their students. That kind of access shouldn’t be rare, and we backed Marble because they’re making it possible at scale.”

As Marble expands nationwide, its platform is also building a powerful data advantage by combining insights from therapists, schools, and families to make its clinical products more precise, personalized, and effective over time.

To learn more, visit https://www.marblehealth.com.

About Marble
Marble Health is a tech-first mental health platform that connects students to high-quality, affordable therapy through their schools. By partnering with school counselors, Marble identifies students in need and matches them with licensed therapists, online or in person, with care covered by insurance. The platform also equips therapists with time-saving tools and enables direct collaboration between counselors and clinicians, ensuring students get the support they need, when they need it.

About Costanoa 
Costanoa exists to elevate founders building companies of consequence. We lead investments from formation through Series A in Applied AI, AI Infrastructure, Cybersecurity, National Security, and Fintech. With $2.3B AUM, we’re boutique by design—making fewer investments to deliver deeper expertise and operational support when it matters most: the early, defining stages of growth. For more information, please visit www.costanoa.vc.

Media contact: [email protected]

SOURCE Marble Health

Round Led by Ambit Health Ventures Positions Smartlens for Market Entry and Future Growth

SUNNYVALE, Calif., Oct. 14, 2025 — Smartlens, Inc., a clinical-stage ophthalmic technology company advancing next-generation glaucoma management devices, today announced the closing of an oversubscribed$5.2 million bridge round led by Ambit Health Ventures. The financing will be used to advance the FDA clearance process and prepare for an expedited market launch following clearance.

The round also included continued participation from existing investors Graphene Ventures and Boutique Venture Partners, along with new investment from Harvard Business School Alumni Angels GNY and a group of leading eye care providers.

miLens is distinguished as the world’s first electronics-free contact lens technology capable of continuous intraocular pressure (IOP) monitoring. Working seamlessly with Smartlens’ AI-powered smartphone imaging platform, miLens captures critical pressure fluctuations and enables data-driven treatment optimization. The company plans to initiate commercial activities following FDA clearance, marking a major milestone in transforming glaucoma care worldwide.

Advancing Toward Commercial Launch

Building on strong clinical progress in its multi-site U.S. pivotal trial, Smartlens has made substantial advancements in regulatory preparation, manufacturing scale-up, and clinical validation.

miLens is the world’s smallest wearable microfluidic device designed as an electronics-free soft contact lens for continuous, real-world monitoring of intraocular pressure outside of clinical settings. An independent, double-blind survey of 166 ophthalmic practitioners conducted by Market Scope showed exceptionally high interest, with 96.2% expressing intent to adopt the technology once available.miLens offers unprecedented insight for patients with glaucoma, ocular hypertension, and those requiring post-surgical intraocular pressure monitoring.

“This financing milestone strengthens our position as we advance through the FDA clearance process and prepare for commercialization,” said Savas Komban, CEO and Co-Founder of Smartlens, Inc. “We’re laying the foundation for the next generation of glaucoma management—one driven by continuous, data-based insight rather than intermittent snapshots. The continued confidence from our investors underscores both the scale of the opportunity ahead and the meaningful impact miLens can have for patients worldwide.”

Addressing a Critical Unmet Need

Together with ocular hypertension, glaucoma affects more than 180 million people worldwide and remains the leading cause of irreversible vision loss. Because elevated intraocular pressure is the primary modifiable risk factor, continuous IOP monitoring has the potential to transform glaucoma management by enabling earlier intervention and personalized therapy. Current clinical practice still relies on infrequent, single-point IOP measurements that often miss critical fluctuations throughout the day and night.

“Smartlens continues to make impressive progress with its technology, and miLens is a true leap forward in ophthalmic innovation,” said Sam Goldberger, MD, MBA, Co-Founder and Managing Partner of Ambit Health Ventures. “We are proud to lead this strategic round as the company advances through the FDA clearance process, positioning Smartlens not just for commercial launch, but to redefine continuous glaucoma monitoring and transform patient care worldwide.”

About miLens

miLens provides a non-invasive, continuous IOP monitoring solution that integrates seamlessly into clinical workflows. The platform’s AI-driven analytics deliver comprehensive pressure profiles and predictive insights, enabling personalized treatment optimization to help prevent disease progression. By offering real-world, continuous data, miLens gives ophthalmologists a new level of visibility into IOP behavior—empowering smarter, earlier, and more effective glaucoma management.

About Smartlens, Inc.

Smartlens, Inc. is an ophthalmic technology company dedicated to transforming anterior segment disease management through breakthrough innovations in continuous monitoring, diagnosis, and treatment optimization. The company’s proprietary platform combines microfluidic contact lens technology with AI-enhanced diagnostics to enable real-time, personalized glaucoma management and future applications for other ocular diseases.

For more information, visit www.smartlens.health

About Ambit Health Ventures

Ambit Health Ventures is a healthcare innovation venture capital firm specializing in early-stage digital health and medtech investments. The firm’s leadership brings deep sector expertise and provides strategic support to portfolio companies driving innovation and improved outcomes across the healthcare ecosystem.

For more information, visit www.ambithealthventures.com

SOURCE Smartlens, Inc.

ATLANTA , Oct. 14, 2025 — KOR, a fintech leader in global reporting services and trade repositories, is pleased to announce the close of its Series B funding round. The round was led by Macquarie Capital Venture Capital, with continued participation from existing investor Mosaik Partners. This investment marks a significant milestone in KOR’s journey to transform trade and transaction reporting and expand its presence across global markets.

The financing round underscores investors’ continued confidence in KOR’s vision to simplify complex compliance requirements for global derivatives and capital markets. With the Series B capital, KOR will accelerate product innovation, scale operations, and continue coverage expansion of global reporting regimes.

“This funding is a strong validation of the progress our team has made in delivering unique, highly differentiated, trusted, high-performance reporting solutions,” said Jonathan Thursby, Founder and CEO of KOR. “We’re excited to accelerate our growth and extension of the most advanced trade reporting platform through our partnership with Macquarie Capital Venture Capital.”

KOR has built momentum with launches across the US, Canada, UK, EU, and APAC. Its platform delivers accuracy, transparency, controls and operational efficiency for institutions navigating increasingly complex reporting obligations in a persistently changing regulatory environment.

The company’s rapid growth has been driven by adoption among top-tier banks, asset managers, trading platforms, and other segments who value KOR’s combination of regulatory expertise and dynamic technology. With this Series B investment, KOR will further expand its world’s best engineering and client success teams, invest in advanced reporting capabilities, and pursue new strategic opportunities.

Green Horizon Partners served as the exclusive financial advisor to KOR.

About KOR

KOR is a US-based fintech company that develops future-minded technology innovations tailored specifically for derivatives markets. KOR Reporting Inc is an operator of global licensed derivative trade repositories. KOR Financial Inc. delivers a full suite of modular services that enable market participants to meet derivatives reporting mandates with unparalleled operational efficiency, user-centric designed systems, full processing transparency, and comprehensive self-service capabilities. Founded in 2021, the KOR team comprises former trade repository heads, top domain SMEs, and technology pioneers, creating a ground-up platform specifically for trade and transaction processing.   

For more information, interested parties can visit www.korfinancial.com  

About Macquarie Capital

Macquarie Capital Venture Capital is the venture unit within Macquarie Capital, the advisory, capital markets and principal investment arm of Macquarie Group. With a successful 30-year track record of combining expertise and capital to accelerate growth, Macquarie Capital Venture Capital partners with founders and invests in early-stage companies to help build them into global, impactful businesses. Leveraging the strength of Macquarie’s balance sheet to lead funding rounds across a company’s full lifecycle, the team focuses on software companies headquartered in Australia, Israel, the United Kingdom and continental Europe that are driving innovation in cybersecurity, compliance, regulatory technology, and artificial intelligence. 

Users can visit Macquarie Capital Venture Capital’s website to learn more. 

About Mosaik Partners

Founded by industry operating executives in 2011, Mosaik Partners invests in early-stage B2B fintech companies attacking pain points in commerce and financial services. Mosaik actively leverages its operating experience to provide promising entrepreneurs with the resources and know-how they need to achieve success. The firm has made investments in the payments, software, capital markets technology, regulatory technology, and AI/big data sectors. Based in San Francisco, the team has a collective 80+ years of operating and investing experience in the financial technology sector.

More information can be found at www.mosaikpartners.com

Contact

Operations Specialist
Savannah Vukelich
KOR
[email protected] 

Photo: https://mma.prnewswire.com/media/2795785/KOR.jpg
Logo:  https://mma.prnewswire.com/media/2795784/KOR_Logo.jpg

SOURCE KOR

Financing  supports ongoing clinical operations, development, and commercialization preparation                  

HALIFAX, NS, Oct. 14, 2025 – ABK Biomedical, Inc., an innovative medical device company dedicated to the research, development, and commercialization of advanced imageable embolic medical devices, today announced an oversubscribed US$35 million Series D financing. The round was led by new investor, J.P. Morgan Life Sciences Private Capital.  Existing investors – F-Prime, Santé Ventures, Eight Roads Ventures, and a significant undisclosed medical device company  – also participated in the round.

The proceeds of the Series D funding round will support ongoing clinical operations, prepare for the commercialization of Eye90 microspheres^®, and drive further product innovation and development. Additional funds will be used to increase the scale and scope of the Company’s manufacturing and supply chain operations to support Eye90 microspheres commercialization well into the future.

“We have been extremely impressed with the progress ABK Biomedical has made dating back to its Series B funding round in 2019,” said Joe Siletto, Managing Partner at J.P. Morgan Life Sciences Private Capital. “ABK’s development of Eye90 microspheres has been recognized by the FDA as a Breakthrough Device Designation, having the potential to more effectively treat life-threatening or irreversibly debilitating diseases or conditions. They are executing well in their Route90 FDA IDE pivotal trial, and we are excited to help support the next steps in their company’s evolution.”

“I am humbled by the outpouring of investor interest in this funding round,” said Mike Mangano, President and CEO of ABK Biomedical.  “We welcome J.P. Morgan Life Sciences Private Capital to our Board of Directors, joining our outstanding syndicate of investors. Our ABK team is a best-in-class organization and continues to achieve our product development goals for our embolic platforms while executing our FDA IDE pivotal trial. Our Route90 PIs, investigators, and research support staff are conducting the study with exceptional rigor, in what we feel will be one of the most robust data sets ever completed within the Interventional Oncology subspecialty. We’re looking forward to our Route90 study demonstrating the breakthrough promise of Eye90 microspheres, offering better care for patients with liver cancer.”

“Our investment began in 2019 and we’re proud of the progress and tremendous collaboration between ABK Biomedical and F-Prime,” said Ketan Patel, M.D., Managing Partner at F-Prime. “The advanced design of Eye90 microspheres, its novel delivery system, forward thinking supply chain, and robust data set are poised to do very well in the marketplace. It is primed to take market share, and drive market development in this Y90 radioembolization double-digit growth segment within the Interventional Oncology device market. We’re excited to build on our investment and partner with ABK in this latest funding raise.”

About ABK Biomedical, Inc.
ABK Biomedical is a company focused on researching, developing and commercializing medical device therapies to improve treatment outcomes and the lives of patients with benign and malignant hypervascular tumors. ABK Biomedical holds intellectual property in the areas of inorganic polymer microspheres and unique administration systems. The company possesses advanced intellectual capital and its own R&D and manufacturing facilities for developing and commercializing unique embolotherapy products. Eye90 microspheres^® is considered an investigational product and is not approved for use in any regulatory jurisdiction outside of approved clinical trials. 

SOURCE ABK Biomedical Inc.